ArticleThe journal of allergy and clinical immunology. Global2025
A randomized comparison of intramuscular high-dose versus oral maintenance vitamin D to prevent severe exacerbations in deficient/insufficient asthmatic children.
Article in The journal of allergy and clinical immunology. Global, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A role for vitamin D supplementation in deficient/insufficient asthmatic children is controversial. Objective: We sought to compare high-dose intramuscular (IM) + daily oral maintenance vitamin D dose versus daily oral maintenance vitamin D dose for preventing asthma exacerbations in prospectively randomized vitamin D-deficient/insufficient children aged 5 to 14 years with moderate to severe asthma. Methods: This is an accessory Results: A total of 122 children aged 5 to 14 years (61 high-dose IM 600,000 IU + Oral and 61 Oral-Only) completed a 12-month treatment. Baseline 25-hydroxyvitamin D level was less than 20 ng/mL in 84% of them. Over months 0 to 12, as the Oral-Only group was slowly repleted, the IM + Oral group remained superior to the Oral-Only group (40 [66%] with unplanned ED visits vs 50 [82%]; relative risk, 0.80 [95% CI, 0.65-1.0]; absolute risk reduction, 16% [95% CI, 1%-31%]; number needed to treat, 6.3). Over months 0 to 3, a secondary outcome, the IM 600,000 IU + Oral supplementation group had a reduction in ED visits compared with the Oral-Only group (21 [34%] vs 38 [58%]; relative risk, 0.55 [95% CI, 0.36-0.84]; absolute risk reduction, 28% [95% CI, 9%-45%]; number needed to treat, 3.4). Conclusions: A dose of IM 600,000 IU vitamin D every 3 months significantly reduced unplanned ED visits for asthma for vitamin D-deficient/insufficient asthmatic children aged 5 to 14 years over months 0 to 12 and months 0 to 3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.